Insmed price target raised to $100 from $85 at Truist

Truist raised the firm’s price target on Insmed to $100 from $85 and keeps a Buy rating on the shares. The firm has conducted a survey to gauge physician interest in brensocatib for bronchiectasis – chronic lung inflammation – in academic and community settings, and from its survey, Truist has greater confidence in the expansion opportunity to comorbid COPD/asthma patients, adding about $1B to its brenso peak sales estimate, the analyst tells investors in a research note.